Favourable response to launches, recovery in CVs will aid growth.
Bharti'suarterly revenue run rate continues to be hover around the $1.2 billion mar
IT and pharma companies again save the day; mask pain in domestic consumption.
Analysts are divided on the deal valuations. Some say Torrent could have bargained harder, as Sanofi, among others, passed it over.
The sharp fall in the rupee's value against the dollar during the July-September quarter, it turns out, has come as a boon for corporate earnings.
Better margins, lower interest outgo could see the company turn profitable in FY15.
Revival in domestic business should also help overall revenue growth.
Given its track record, cautious analysts are monitoring progress on these fronts.
While domestic sales in the second quarter are expected to be weak for major players, Lupin is likely to outperform the pharma sector on the back of a growing chronic portfolio.
Severe price cuts help multinationals ramp up growth, gain market share.
Aggressive smaller players are serving a bitter pill to the big boys in the pharmaceutical sector.
Footfalls increase at retail outlets and auto dealers, but conversions fall.
Companies together have lost about Rs 20,000 crore (Rs 200 billion) in market value since the arrest of former telecom minister, A Raja, leading to historically low valuations.
India's largest pharma companies by market capitalisation Sun Pharma, Dr Reddy's and Cipla have seen their share prices drop 5-20 per cent over the last two weeks on results that were below Street expectations.
The BSE Realty index fell 11 per cent over the last month and eight per cent over the week as real estate companies reported margin pressures in the September quarter.
The Street has welcomed the sustained demand and higher sales for two-wheeler makers in September by pushing up stock prices of the three key companies by three to seven per cent over the past week.
While demand for consumer durables has been growing fast, investors need to be selective as stock valuations have risen even faster.
With the broader indices continuing to power ahead and valuations trading at a premium, investors tend to look at small and mid-cap companies for bargains.
Following a strategy that is different from the herd could help increase returns in a market trading at premium valuations.
A rise in consumer confidence, improvement in profitability and aggressive expansion plans signal better tidings for listed players in the organised retail space.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances